New York, June 5, 2026, 15:02 (EDT)
- Curanex Pharmaceuticals shares last traded at $0.3104, down about 6.5%, with volume near 100,000 shares.
- The Nasdaq-listed drug developer remains below the $1 minimum bid level and has until Nov. 2 to regain compliance.
- Its lead drug, Phyto-N, is still preclinical, with a planned FDA investigational new drug application in the fourth quarter.
Curanex Pharmaceuticals Inc shares fell on Friday, leaving the small drug developer well below Nasdaq’s $1 minimum bid threshold as investors weighed a thinly traded stock, a still-preclinical pipeline and a broader selloff in biotechnology.
The stock last traded at $0.3104, down 2.16 cents, or about 6.5%, from the prior close. It opened at $0.3224, touched $0.3233 and fell as low as $0.3089, with volume of 99,708 shares and a market value of about $8.8 million. The SPDR S&P Biotech ETF was down about 3.6%, while the iShares Nasdaq Biotechnology ETF slipped about 1.4%.
The move matters now because the share price is not just a market signal. Curanex disclosed last month that Nasdaq had given it a second 180-day period, until Nov. 2, 2026, to regain compliance with the exchange’s $1 minimum bid rule. The company said it may use a reverse stock split, if needed; that means reducing the number of shares outstanding to lift the per-share price mechanically.
Curanex is a development-stage pharmaceutical company based in Jericho, New York. Its lead asset, Phyto-N, is being developed first for ulcerative colitis, a chronic inflammatory disease of the large intestine.
The company’s latest substantive update came on May 14, when it said it had completed a pilot-scale batch of Phyto-N under Good Manufacturing Practice standards and a dose-range toxicology study in rats and dogs. Good Manufacturing Practice, or GMP, refers to quality rules for making drug material; toxicology work tests safety before human studies.
“Curanex made meaningful progress during the first quarter as we continued advancing Phyto-N toward a planned FDA submission,” Chief Executive Jun Liu said in that release. Liu added that, “If allowed to proceed, that submission would position Phyto-N to enter human clinical testing.” GlobeNewswire
The planned filing is an investigational new drug application, or IND, which is the request to the U.S. Food and Drug Administration to begin testing a drug in people. Curanex has said it is targeting the fourth quarter of 2026 for that submission.
The financial runway remains a focus. In its March-quarter filing, Curanex reported $4.0 million in cash and cash equivalents at March 31, down from $5.0 million at year-end, and a first-quarter net loss of $3.15 million, compared with a loss of $137,583 a year earlier. It used $954,560 in operating cash during the quarter.
The competitive bar in ulcerative colitis is high. AbbVie’s Skyrizi, Eli Lilly’s Omvoh and Pfizer’s Velsipity are already approved in the United States for adults with moderately to severely active ulcerative colitis, leaving Curanex far earlier in development than larger rivals with marketed products.
A fresh read-across for the sector came from Abivax, another ulcerative-colitis drug developer, whose shares dropped sharply this week after strong late-stage trial data were overshadowed by safety questions. Leerink Partners analyst Thomas Smith called Abivax’s data a “best-case scenario,” Investor’s Business Daily reported, but the market reaction showed how quickly safety doubts can hit even more advanced bowel-disease programs. Investors
But the risk case for Curanex is more basic: the company must execute preclinical work, win FDA clearance to begin human testing, keep enough cash to fund studies and fix its Nasdaq bid-price issue. Failure on any of those points could pressure the stock further or force financing on terms that dilute existing holders.
For now, the stock’s price action is doing the talking. The next hard catalysts are likely regulatory preparation, any financing or listing-compliance step, and whether Phyto-N reaches the FDA filing stage on the timetable management has set.
